Form 4: Adaptive Bio CFO Kyle Piskel Exercises, Sells ADPT Stock

Adaptive Biotechnologies CFO Kyle Piskel exercised stock options and immediately sold an equivalent number of shares under a pre-arranged 10b5-1 trading plan.

Summary

• Kyle Piskel, Chief Financial Officer of Adaptive Biotechnologies Corp (ADPT), executed a transaction on February 4, 2026.
• The transaction involved the exercise of 2,145 stock options at an exercise price of $12.14 per share.
• Concurrently, Mr. Piskel sold 2,145 shares of common stock at a price of $18.46 per share.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on August 28, 2025.
• Following these transactions, Mr. Piskel's direct beneficial ownership of common stock is 216,637 shares, and he retains 2,146 derivative securities (stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it involves an insider sale, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling, and the CFO retains a significant stake, indicating continued alignment.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned personal financial management rather than a reaction to new, undisclosed information.
• The CFO continues to hold a substantial number of common shares (216,637) and additional stock options (2,146), maintaining a significant ownership stake in the company.

Negatives

• An insider sale, even if planned, reduces the direct ownership stake of a key executive, which some investors may interpret as a slight reduction in direct alignment with shareholder interests.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that routine insider transactions, particularly those executed under pre-arranged 10b5-1 plans, are common across various industries. These plans allow insiders to sell shares over time without concerns about trading on material non-public information, reflecting personal financial planning rather than a specific market outlook.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a pre-arranged plan, which typically has minimal impact on shareholder sentiment. The CFO's continued significant ownership stake suggests ongoing alignment of interests.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Keywords

Adaptive Biotechnologies, ADPT, Kyle Piskel, CFO, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan